A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Amyotrophic lateral sclerosis; Chronic lymphocytic leukaemia; Dermatomyositis; Giant cell arteritis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Polymyositis; Rheumatoid arthritis; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Roche
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 01 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2016 New trial record